drugset / Trial / NCT02978859
Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate Sitravatinib, an oral small molecular receptor tyrosine kinase inhibitor, for the treatment of advanced liposarcoma.
Timeline
- Start
- 2016-11
- Primary completion
- 2020-01
- Completion
- 2021-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sitravatinib | Small molecule | 150 mg | Oral |